xaliplatin-based combination regimens have demonstrated a prolonged disease progression-free and overall survival in colorectal cancer patients, in both the adjuvant and advanced or metastatic setting. Peripheral neuropathy is currently recognized to be among the major and dose-limiting non-hematological adverse events of OXA treatment. Until now, no reliable genetic or molecular biomarkers have been identified to date with which to detect those patients at high risk of developing OXA-induced peripheral neurotoxicity. The current multicenter study is designed to investigate, in a prospective cohort of well-characterized CRC patients, candidate single nucleotide polymorphisms (SNPs) in genes coding for neurologically relevant targets, with the aim of identifying reliable predictors and risk factors of oxaliplatin-induced peripheral neurotopathy.
Project leaders: Armando Genazzani, Salvatore Terrazzino.
Clinical Centers: Guido Cavaletti (Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy); Andreas Argyriou (Department of Neurology, “Saint Andrew’s” General Hospital of Patras, Greece).
Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. J Peripher Nerv Syst 2015;20:15-23.
Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 2013;119(19):3570-7.